Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19070930 | RAS INHIBITORS | March 2025 | June 2025 | Allow | 3 | 1 | 0 | No | No |
| 19062331 | RAS INHIBITORS | February 2025 | June 2025 | Allow | 3 | 1 | 0 | No | No |
| 19053277 | ADVANTAGEOUS BENZOFURAN COMPOSITIONS FOR MENTAL DISORDERS OR ENHANCEMENT | February 2025 | April 2025 | Allow | 2 | 0 | 0 | No | No |
| 18895095 | ADVANTAGEOUS BENZOFURAN COMPOSITIONS FOR MENTAL DISORDERS OR ENHANCEMENT | September 2024 | February 2025 | Allow | 5 | 1 | 0 | No | No |
| 18790708 | PSYCHOACTIVE MEDICINES AND THEIR USE FOR TREATING PSYCHIATRIC AND NEUROLOGICAL CONDITIONS AND DISORDERS | July 2024 | March 2025 | Allow | 8 | 1 | 1 | Yes | No |
| 18784243 | PSYCHOACTIVE MEDICINES AND THEIR USE FOR TREATING PSYCHIATRIC AND NEUROLOGICAL CONDITIONS AND DISORDERS | July 2024 | April 2025 | Allow | 8 | 2 | 0 | No | No |
| 18652721 | COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES AND DISORDERS | May 2024 | February 2025 | Allow | 9 | 0 | 1 | No | No |
| 18603816 | OXYSTEROLS AND METHODS OF USE THEREOF | March 2024 | December 2024 | Allow | 9 | 1 | 0 | No | No |
| 18425761 | LYMPHATIC SYSTEM-DIRECTING LIPID PRODRUGS | January 2024 | July 2024 | Allow | 6 | 1 | 0 | No | No |
| 18573439 | APPLICATION OF CB-839 IN PREPARATION OF DRUG FOR INHIBITING CORNEAL NEOVASCULARIZATION (CNV) | December 2023 | July 2024 | Allow | 7 | 1 | 0 | Yes | No |
| 18390195 | MULTI-SUBSTITUENT PSILOCYBIN DERIVATIVES AND METHODS OF USING | December 2023 | June 2024 | Allow | 6 | 1 | 0 | Yes | No |
| 18390228 | MULTI-SUBSTITUENT PSILOCYBIN DERIVATIVES AND METHODS OF USING | December 2023 | June 2024 | Allow | 6 | 1 | 0 | Yes | No |
| 18518292 | METHOD OF MODULATING TIGIT AND PD-1 SIGNALLING PATHWAYS USING 1,2,4-OXADIAZOLE COMPOUNDS | November 2023 | March 2024 | Allow | 4 | 1 | 0 | No | No |
| 18387180 | DRUG COMBINATION AND USE FOR TREATING TUMORS | November 2023 | March 2024 | Allow | 4 | 1 | 0 | No | No |
| 18386337 | PSYCHOACTIVE MEDICINES AND THEIR USE FOR TREATING PSYCHIATRIC AND NEUROLOGICAL CONDITIONS AND DISORDERS | November 2023 | March 2024 | Allow | 4 | 1 | 0 | No | No |
| 18371935 | ADVANTAGEOUS BENZOFURAN COMPOSITIONS FOR MENTAL DISORDERS OR ENHANCEMENT | September 2023 | February 2025 | Allow | 17 | 1 | 0 | No | No |
| 18280132 | PREPARATION METHOD AND APPLICATION OF NOVEL INJECTION ABIRATERONE DERIVATIVE | September 2023 | November 2023 | Allow | 2 | 0 | 0 | Yes | No |
| 18454922 | COMBINED USE OF IN10018 AND PLD | August 2023 | August 2024 | Allow | 12 | 3 | 0 | Yes | No |
| 18215547 | PSYCHOACTIVE MEDICINES AND THEIR USE FOR TREATING PSYCHIATRIC AND NEUROLOGICAL CONDITIONS AND DISORDERS | June 2023 | June 2024 | Allow | 12 | 2 | 1 | Yes | No |
| 18343182 | TREATMENT AND PREVENTION OF SLEEP DISORDERS | June 2023 | March 2025 | Allow | 20 | 1 | 0 | Yes | No |
| 18342312 | COMPOUNDS AND USE THEREOF IN METHODS OF TREATMENT | June 2023 | May 2025 | Allow | 23 | 1 | 0 | Yes | No |
| 18320264 | CYCLIC ETHER DERIVATIVES OF PYRAZOLO[1,5-A]PYRIMIDINE-3-CARBOXYAMIDE | May 2023 | March 2025 | Allow | 22 | 1 | 0 | No | No |
| 18133189 | PHARMACOKINETICS OF NMDA RECEPTOR ANTAGONISTS | April 2023 | June 2025 | Abandon | 26 | 4 | 0 | No | No |
| 18133201 | REDUCED SEDATION AND DISSOCIATION IN TREATING NEUROLOGICAL DISORDERS | April 2023 | June 2025 | Abandon | 26 | 4 | 0 | No | No |
| 18131570 | ADMINISTRATION AND DOSAGE OF DIAMINOPHENOTHIAZINES | April 2023 | January 2025 | Allow | 22 | 1 | 0 | Yes | No |
| 18194038 | COMBINATION OF DEXTROMETHORPHAN AND BUPROPION FOR TREATING DEPRESSION | March 2023 | March 2024 | Abandon | 12 | 2 | 0 | No | No |
| 18188966 | RAS INHIBITORS | March 2023 | January 2025 | Allow | 22 | 1 | 0 | No | No |
| 18188689 | COMBINATION OF DEXTROMETHORPHAN AND BUPROPION FOR TREATING DEPRESSION | March 2023 | April 2024 | Abandon | 13 | 2 | 0 | No | No |
| 18159232 | PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM | January 2023 | January 2024 | Allow | 11 | 3 | 0 | Yes | No |
| 18152255 | Dosage Regimen for the Treatment of Cancer | January 2023 | March 2025 | Allow | 26 | 1 | 0 | Yes | No |
| 18147856 | PHARMACEUTICAL COMPOSITIONS OF 6-(2-(2H-TETRAZOL-5-YL)ETHYL)-6-FLUORODECAHYDROISOQUINOLINE-3-CARBOXYLIC ACID AND ESTER DERIVATIVES THEREOF | December 2022 | April 2023 | Allow | 3 | 0 | 0 | Yes | No |
| 18067387 | ORGANIC COMPOUNDS | December 2022 | November 2024 | Allow | 23 | 1 | 0 | No | No |
| 18066739 | BUPROPION AS A MODULATOR OF DRUG ACTIVITY | December 2022 | September 2023 | Allow | 9 | 1 | 0 | No | No |
| 18077966 | ADVANTAGEOUS BENZOFURAN COMPOSITIONS FOR MENTAL DISORDERS OR ENHANCEMENT | December 2022 | March 2023 | Allow | 4 | 0 | 0 | No | No |
| 18063261 | BUPROPION AS A MODULATOR OF DRUG ACTIVITY | December 2022 | February 2024 | Allow | 14 | 3 | 0 | No | No |
| 17922892 | CYCLOSERINE AND PENTOXIFYLLINE COMBINATION THERAPY FOR TREATMENT OF DEPRESSION | November 2022 | May 2025 | Allow | 30 | 0 | 0 | No | No |
| 18047408 | SALTS AND CRYSTALLINE FORMS OF AN APOPTOSIS-INDUCING AGENT | October 2022 | February 2025 | Abandon | 28 | 1 | 0 | No | No |
| 17966646 | METHOD FOR OPTIMIZING 5-HYDROXYTRYPTAMINE FUNCTION IN THE BRAIN FOR THERAPEUTIC PURPOSES | October 2022 | May 2023 | Allow | 7 | 1 | 0 | Yes | No |
| 17961765 | ADMINISTRATION AND DOSAGE OF DIAMINOPHENOTHIAZINES | October 2022 | May 2024 | Allow | 20 | 1 | 0 | Yes | No |
| 17938353 | METHODS OF TREATING GASTROINTESTINAL STROMAL TUMORS | October 2022 | January 2023 | Allow | 3 | 1 | 0 | No | No |
| 17956139 | MULTI-SUBSTITUENT PSILOCYBIN DERIVATIVES AND METHODS OF USING | September 2022 | November 2023 | Allow | 13 | 2 | 0 | Yes | No |
| 17943567 | PHARMACEUTICAL COMPOSITIONS COMPRISING PERILLYL ALCOHOL DERIVATIVES | September 2022 | January 2025 | Abandon | 28 | 1 | 0 | No | No |
| 17942657 | ROLES OF MODULATORS OF INTERSECTIN-CDC42 SIGNALING IN ALZHEIMER'S DISEASE | September 2022 | December 2024 | Allow | 27 | 1 | 1 | No | No |
| 17823439 | COMPOSITIONS AND METHODS OF USING TYROSINE KINASE INHIBITORS | August 2022 | January 2025 | Abandon | 29 | 1 | 0 | No | No |
| 17894809 | OPHTHALMIC COMPOSITIONS | August 2022 | March 2023 | Allow | 7 | 1 | 0 | Yes | No |
| 17887962 | PSYCHOACTIVE MEDICINES AND THEIR USE FOR TREATING PSYCHIATRIC AND NEUROLOGICAL CONDITIONS AND DISORDERS | August 2022 | May 2023 | Allow | 9 | 1 | 0 | Yes | No |
| 17882939 | METHODS OF INCREASING TONIC INHIBITION AND TREATING SECONDARY INSOMNIA | August 2022 | January 2025 | Abandon | 29 | 1 | 0 | No | No |
| 17882695 | METHODS AND COMPOSITIONS FOR TREATING B-CELL MALIGNANCIES | August 2022 | June 2023 | Allow | 10 | 0 | 0 | No | No |
| 17817927 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | August 2022 | March 2024 | Allow | 20 | 1 | 0 | No | No |
| 17858889 | OPHTHALMIC COMPOSITIONS | July 2022 | December 2022 | Allow | 5 | 1 | 0 | No | No |
| 17850322 | PHARMACEUTICAL FORMULATIONS OF IMATINIB AND USES THEREOF | June 2022 | May 2023 | Allow | 11 | 2 | 0 | No | No |
| 17850463 | COUMARIN DERIVATIVE FOR THERAPY OR PROPHYLAXIS OF A CELL PROLIFERATIVE DISORDER | June 2022 | April 2025 | Allow | 34 | 2 | 0 | Yes | No |
| 17842632 | CRYSTALLINE FORMS OF C21H22Cl2N4O2 | June 2022 | August 2024 | Allow | 26 | 1 | 0 | No | No |
| 17841433 | OPHTHALMIC COMPOSITIONS | June 2022 | December 2024 | Abandon | 30 | 1 | 0 | No | No |
| 17837790 | PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM | June 2022 | October 2022 | Allow | 5 | 1 | 0 | No | No |
| 17833829 | CONTROLLING EFFECTS AFTER 5HT2A AGONISTS ADMINISTRATION | June 2022 | May 2025 | Abandon | 35 | 2 | 1 | No | No |
| 17825783 | COMPOSITIONS AND METHODS FOR TREATING NEGATIVE SYMPTOMS IN NON-SCHIZOPHRENIC PATIENTS | May 2022 | December 2024 | Abandon | 31 | 1 | 0 | No | No |
| 17749583 | METHOD OF TREATING OCULAR DISORDERS WITH COMPOUNDS FOUND IN HARDERIAN GLAND SECRETIONS | May 2022 | August 2024 | Allow | 27 | 1 | 0 | No | No |
| 17662979 | METHOD OF TREATING LIVER FIBROSIS | May 2022 | November 2024 | Abandon | 30 | 1 | 0 | No | No |
| 17736434 | PHARMACEUTICAL COMPOSITION COMPRISING MACITENTAN FOR THE TREATMENT OF CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION | May 2022 | November 2022 | Allow | 6 | 1 | 0 | No | No |
| 17725465 | METABOLICALLY STABLE PYRIMIDINYL DIHYDROQUINOXALINONES AS TUBULIN POLYMERIZATION INHIBITORS | April 2022 | March 2025 | Allow | 35 | 4 | 1 | Yes | No |
| 17713949 | COMPOUNDS AND METHODS FOR TREATING CANCER | April 2022 | December 2024 | Allow | 33 | 2 | 0 | No | No |
| 17699408 | COMPOUNDS AND THEIR USE FOR THE TREATMENT OF ALPHA1-ANTITRYPSIN DEFICIENCY | March 2022 | September 2024 | Allow | 30 | 1 | 0 | No | No |
| 17687816 | METHOD OF REDUCING ABERRANT IMMUNE RESPONSE OR RISK OF PROGRESSION IN COVID-19 | March 2022 | January 2023 | Abandon | 10 | 1 | 0 | No | No |
| 17676666 | Uses of Bcl-2 Antagonists for Treating Cancer and Diagnostics Related Thereto | February 2022 | March 2025 | Allow | 37 | 1 | 0 | No | No |
| 17634610 | URACIL DERMAL PHARMACEUTICAL FORMULATION | February 2022 | May 2025 | Allow | 39 | 0 | 0 | No | No |
| 17581292 | BUPROPION AS A MODULATOR OF DRUG ACTIVITY | January 2022 | September 2022 | Allow | 8 | 1 | 0 | No | No |
| 17574378 | BUPROPION AS A MODULATOR OF DRUG ACTIVITY | January 2022 | September 2022 | Allow | 8 | 1 | 0 | No | No |
| 17560732 | 19-NOR C3, 3-DISUBSTITUTED C21-N-PYRAZOLYL STEROIDS AND METHODS OF USE THEREOF | December 2021 | September 2024 | Allow | 33 | 1 | 0 | No | No |
| 17558204 | COMBINATIONS FOR THE TREATMENT OF NEOPLASMS USING QUIESCENT CELL TARGETING AND INHIBITORS OF MITOSIS | December 2021 | August 2024 | Abandon | 32 | 1 | 0 | No | No |
| 17556869 | COMBINATIONS FOR THE TREATMENT OF NEOPLASMS USING QUIESCENT CELL TARGETING WITH EGFR INHIBITORS | December 2021 | August 2024 | Abandon | 32 | 1 | 0 | No | No |
| 17550706 | METHODS OF TREATING CANCER WITH METABOLITE ADJUSTMENTS | December 2021 | February 2024 | Abandon | 26 | 1 | 1 | No | No |
| 17547472 | METHODS OF TREATING HIV-ASSOCIATED NEUROLOGICAL DISORDERS (HAND) | December 2021 | July 2023 | Allow | 19 | 1 | 1 | No | No |
| 17545377 | JAK1 PATHWAY INHIBITORS FOR THE TREATMENT OF VITILIGO | December 2021 | December 2023 | Allow | 24 | 3 | 0 | No | No |
| 17543504 | METHODS FOR PREVENTING TOXICITY OF PLATINUM DRUGS | December 2021 | September 2024 | Abandon | 34 | 1 | 0 | No | No |
| 17530967 | 1-((S)-1-(3-CHLORO-5-FLUORO-2-((4-(1H-PYRAZOL-1-YL)-2-METHYLQUINOLIN-8-YLOXY)METHYL)PHENYL)ETHYL)-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AND RELATED COMPOUNDS AS BRADYKININ (BK) B2 RECEPTOR ANTAGONIST FOR TREATING SKIN DISEASES | November 2021 | January 2025 | Allow | 38 | 0 | 1 | Yes | No |
| 17612931 | COMPOSITIONS AND METHODS FOR CELLULAR DELIVERY | November 2021 | July 2024 | Allow | 32 | 1 | 1 | No | No |
| 17526676 | BUPROPION AS A MODULATOR OF DRUG ACTIVITY | November 2021 | August 2022 | Allow | 9 | 1 | 0 | No | No |
| 17525339 | BUPROPION AS A MODULATOR OF DRUG ACTIVITY | November 2021 | July 2022 | Allow | 8 | 1 | 0 | No | No |
| 17501620 | C-MET REGULATORY COMPOSITION AND ITS METHOD FOR TREATING LIVER DISEASE | October 2021 | November 2022 | Allow | 13 | 0 | 0 | Yes | No |
| 17500367 | (4-((3R,4R)-3-METHOXYTETRAHYDRO-PYRAN-4-YLAMINO)PIPERIDIN-1-YL)(5-METHYL-6-(((2R,6S)-6-(P-TOLYL)TETRAHYDRO-2H-PYRAN-2-YL)METHYLAMINO)PYRIMIDIN-4-YL)METHANONE CITRATE | October 2021 | April 2024 | Allow | 30 | 1 | 0 | Yes | No |
| 17491836 | 1,4-DIHYDROPYRIDINE COMPOSITIONS, METHODS OF MAKING AND USE | October 2021 | June 2025 | Allow | 44 | 1 | 0 | No | No |
| 17490650 | METHODS OF INCREASING TONIC INHIBITION AND TREATING SECONDARY INSOMNIA | September 2021 | July 2024 | Abandon | 34 | 1 | 0 | No | No |
| 17488041 | ALCOHOL-BASED COMPOSITIONS AND USES THEREOF | September 2021 | January 2024 | Allow | 28 | 1 | 0 | No | No |
| 17478029 | PREVENTION OF HIV-INFECTION | September 2021 | July 2024 | Abandon | 34 | 1 | 0 | No | No |
| 17476269 | RAS INHIBITORS | September 2021 | February 2023 | Allow | 17 | 1 | 0 | No | No |
| 17472422 | PYRAZINE-CONTAINING COMPOUND | September 2021 | May 2022 | Allow | 8 | 1 | 0 | No | No |
| 17466111 | PSILOCYBIN IN PATIENTS WITH OBSESSIVE-COMPULSIVE DISORDER | September 2021 | June 2024 | Abandon | 34 | 3 | 0 | No | No |
| 17459373 | Method for Treating Nasal, Sinonasal, and Nasopharyngeal Tissue Infection and/or Inflammation | August 2021 | June 2024 | Allow | 34 | 0 | 0 | No | No |
| 17445817 | STABLE CRYSTAL OF 4-OXOQUINOLINE COMPOUND | August 2021 | April 2024 | Abandon | 32 | 1 | 0 | No | No |
| 17405543 | Ferric Organic Compounds, Uses Thereof and Methods of Making Same | August 2021 | June 2024 | Abandon | 34 | 1 | 0 | No | No |
| 17429902 | COMBINATIONS WITH THIAZOLIDINEDIONES FOR USE IN THE PREVENTION OR TREATMENT OF ABNORMAL BONE GROWTH | August 2021 | August 2024 | Allow | 37 | 1 | 0 | No | No |
| 17389940 | 1,2,4-TRIAZIN-3(2H)-ONE COMPOUNDS FOR THE TREATMENT OF HYPERPROLIFERATIVE DISEASES | July 2021 | February 2025 | Allow | 42 | 1 | 1 | No | No |
| 17443769 | USE OF LEVOCETIRIZINE AND MONTELUKAST IN THE TREATMENT OF TRAUMATIC INJURY | July 2021 | June 2024 | Abandon | 35 | 1 | 0 | No | No |
| 17425576 | PHARMACEUTICAL COMPOSITION COMPRISING MACITENTAN FOR THE TREATMENT OF CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION | July 2021 | October 2024 | Abandon | 39 | 1 | 0 | No | No |
| 17384345 | POLYMOROPHS OF 5-AZA-4'-THIO-2'-DEOXYCYTIDINE | July 2021 | July 2022 | Allow | 12 | 0 | 0 | No | No |
| 17380413 | METHOD OF INITIATING OR ESCALATING DOFETILIDE DOSE AND FORMULATIONS THEREFOR | July 2021 | December 2023 | Allow | 29 | 0 | 0 | Yes | No |
| 17379999 | INJECTABLE FOSAPREPITANT COMPOSITION | July 2021 | April 2024 | Allow | 33 | 2 | 0 | No | No |
| 17423248 | COMPOUND FOR INHIBITING PGE2/EP4 SIGNALING TRANSDUCTION INHIBITING, PREPARATION METHOD THEREFOR, AND MEDICAL USES THEREOF | July 2021 | September 2024 | Allow | 38 | 1 | 1 | Yes | No |
| 17371564 | BINGE BEHAVIOR REGULATORS | July 2021 | February 2025 | Allow | 44 | 2 | 0 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner VALENROD, YEVGENY.
With a 0.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 20.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner VALENROD, YEVGENY works in Art Unit 1628 and has examined 493 patent applications in our dataset. With an allowance rate of 82.6%, this examiner has a below-average tendency to allow applications. Applications typically reach final disposition in approximately 28 months.
Examiner VALENROD, YEVGENY's allowance rate of 82.6% places them in the 49% percentile among all USPTO examiners. This examiner has a below-average tendency to allow applications.
On average, applications examined by VALENROD, YEVGENY receive 1.59 office actions before reaching final disposition. This places the examiner in the 42% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.
The median time to disposition (half-life) for applications examined by VALENROD, YEVGENY is 28 months. This places the examiner in the 49% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a +18.2% benefit to allowance rate for applications examined by VALENROD, YEVGENY. This interview benefit is in the 64% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.
When applicants file an RCE with this examiner, 35.5% of applications are subsequently allowed. This success rate is in the 75% percentile among all examiners. Strategic Insight: RCEs are highly effective with this examiner compared to others. If you receive a final rejection, filing an RCE with substantive amendments or arguments has a strong likelihood of success.
This examiner enters after-final amendments leading to allowance in 46.8% of cases where such amendments are filed. This entry rate is in the 65% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants request a pre-appeal conference (PAC) with this examiner, 85.7% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 63% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.
This examiner withdraws rejections or reopens prosecution in 88.9% of appeals filed. This is in the 79% percentile among all examiners. Of these withdrawals, 81.2% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 31.8% are granted (fully or in part). This grant rate is in the 24% percentile among all examiners. Strategic Note: Petitions are rarely granted regarding this examiner's actions compared to other examiners. Ensure you have a strong procedural basis before filing a petition, as the Technology Center Director typically upholds this examiner's decisions.
Examiner's Amendments: This examiner makes examiner's amendments in 12.2% of allowed cases (in the 97% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 2.5% of allowed cases (in the 68% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.